TLRY · Tilray Brands, Inc. · Stock research

Current Thesis

The event that justified owning TLRY has come and gone without producing an event. The DEA's expedited rescheduling hearing opened 2026-06-29 and closed 2026-07-15, and Chief ALJ Derek Julius adjourned it not with a recommendation but with a briefing schedule: post-hearing briefs of up to 50 pages due 2026-08-17, after which he will write a recommendation on no stated timeline, with the final call resting with the DEA Administrator. Broad adult-use Schedule III is now a multi-month administrative process with a litigation tail, not a dated catalyst. Price behaved accordingly — TLRY printed a fresh 52-week low of $4.20 on 2026-07-08 and has traded $4.35–4.38 since, below the 200-day, with TD Cowen cutting its target to $5 from $7 on 2026-07-14 while keeping a Buy. What remains is a $1.2B-annualized beverage-and-cannabis conglomerate with one genuinely growing leg (international medical) reporting Q4/FY2026 after the close on 2026-07-28 against a consensus of roughly -$0.01. That is an earnings print, not a reform trade, and the calendar is inside the window where fresh positioning is a coin flip.

Bullish and bearish views on Tilray Brands, Inc.

The model's bull view on Tilray Brands, Inc. (TLRY), in brief: International cannabis is the only accelerating leg and it is accelerating hard: Q3 FY2026 (reported ~2026-04-01) showed international cannabis +70% YoY on German legalization volumes, inside record net revenue of $206.7M (+11%) and gross profit of $55M (+6%). The bear view: The hearing produced a briefing calendar, not a decision. Both cases follow in full.

Bull Case

• International cannabis is the only accelerating leg and it is accelerating hard: Q3 FY2026 (reported ~2026-04-01) showed international cannabis +70% YoY on German legalization volumes, inside record net revenue of $206.7M (+11%) and gross profit of $55M (+6%). (Q3 FY2026 release)
• Geographic expansion continues without needing US reform: Tilray Medical launched its first medical cannabis product in Panama on 2026-07-09, extending the medical footprint into Latin America.
• Management reaffirmed FY2026 adjusted EBITDA guidance of $62–72M at the Q3 print — a company generating positive adjusted EBITDA rather than a pure cash-burn LP.
• BrewDog adds roughly $200M of annual net revenue and $6–8M of FY2027 adjusted EBITDA, lifting global consolidated net revenue to ~$1.2B annualized and giving the platform a non-cannabis cash contributor.
• The hemp cleanup is still coming: the Continuing Appropriations Act signed 2025-11-12 recriminalizes most intoxicating hemp-derived THC effective ~2026-11-12, with the U.S. Hemp Roundtable estimating ~95% of current hemp-cannabinoid products swept out — removing the gray-market undercut on licensed product.
• The 2026-04-23 DOJ Final Order already moved FDA-approved cannabis drugs and state-licensed medical marijuana to Schedule III, with the registration window closing 2026-06-22. The administration has demonstrated it will act, which keeps the broader outcome live rather than theoretical.
• Sell-side has not capitulated: consensus target sits around $6.33 versus a $4.35 tape, and TD Cowen held its Buy through the target cut.

Bear Case

• The hearing produced a briefing calendar, not a decision. Briefs are due 2026-08-17, the ALJ set no date for his recommendation, and the DEA Administrator holds the final pen — with the losing side's litigation option intact. The date that anchored the trade is spent.
• Price made a new 52-week low on 2026-07-08 at $4.20, during the hearing itself. A market that will not bid a name while its bullish catalyst is being heard in open session is telling the operator what it thinks of the outcome.
• Shares lost roughly 11% over the trailing month against a Medical-sector gain of ~4.3% and an S&P 500 gain of ~1.3% — underperformance into the catalyst, not accumulation.
• TD Cowen's 2026-07-14 target cut to $5 from $7 is a 29% haircut on a maintained Buy. Estimates are being marked down toward the tape, not the tape toward estimates.
• Reform beta is structurally diluted. With BrewDog folded in, cannabis is roughly 31% of consolidated revenue; a favorable Schedule III outcome moves less than a third of the P&L, while the beverage business carries its own margin problems.
• The round trip from ~$5 to ~$23 and back to ~$4 leaves overhead supply stacked at every level a recovery would have to clear, and reliably converts each reform headline into a distribution event.
• Q4/FY2026 lands 2026-07-28 after the close with consensus near -$0.01, a ~105% swing from the year-ago quarter. Dilution is ongoing — the Lyphe Group acquisition was funded with ~1.6M new shares in early June 2026 alongside a debt-for-equity retirement of $6M of 2027 converts.

Setup & Price Structure

The structure is broken and has been for months. TLRY trades ~$4.35–4.38 as of 2026-07-16, below the 200-day SMA, having set a new 52-week low at $4.20 on 2026-07-08 — the prior $4.50 shelf that the April hearing low defended is gone. There is no higher low, no base, and no reclaim attempt to lean on. Every technical requirement for a momentum entry is unmet: the name needs a daily close back above the ~$5.80–6.00 area to put the 200-day back in play, which is 33–38% away. Between here and there sits the consensus target of $6.33 and TD Cowen's freshly cut $5, both above spot, which is the ordinary condition for a value trap rather than evidence of upside. A long from these levels is a bet that a 52-week-low print eight trading days before an earnings release marks the bottom.

Catalyst Calendar (next 30 days)

• 2026-08-17 (confirmed) — Post-hearing briefs due in the DEA rescheduling proceeding, 50-page cap, closing arguments included. This is a filing deadline, not a ruling; the ALJ recommendation follows on no announced schedule.
• No dated decision point exists between now and the ALJ recommendation. Any move on rescheduling headlines in this window is sentiment, not resolution.

Elapsed catalysts

• 2026-07-28 (confirmed, after close) — Q4 and full-year FY2026 results for the period ended 2026-05-31; conference call 4:30 PM ET. Consensus EPS ~-$0.01. Key lines: whether FY adjusted EBITDA lands inside the reaffirmed $62–72M band, international cannabis growth versus the +70% Q3 comp, and first hard BrewDog contribution detail. (passed 12d ago)
• 2026-07-28 → 2026-07-29 — FY2027 guidance, the first framing of the ~$1.2B annualized consolidated revenue base and the $6–8M BrewDog adjusted-EBITDA contribution. (passed 11d ago)

What Would Change Our Mind

A daily close above $5.00 that reclaims the TD Cowen target level would be the first structural evidence in months, and a sustained daily close above $6.00 would put the 200-day back in play and turn this from a falling knife into an actual setup. Fundamentally, a Q4 print on 2026-07-28 that holds international cannabis growth near the +70% Q3 pace while landing FY adjusted EBITDA at the top of the $62–72M band — and guides FY2027 above the ~$1.2B annualized run-rate — would argue the operating business is compounding independent of Washington. On the policy side, an ALJ recommendation explicitly endorsing broad adult-use Schedule III, arriving before the hemp recriminalization date of ~2026-11-12, would restore the reform leg that the 2026-07-15 adjournment removed. Absent any of those, the name is a pass and the correct behavior on weakness is to stand aside, not to accumulate.

Correlation Notes

• Trades as high-beta expression of the US cannabis-reform complex alongside CGC, CRON, ACB and the MSOS basket; single-name work is largely wasted because reform headlines move the group in lockstep.
• Peer read-through is negative on quality: Canopy's FY2026 print (2026-06-15) paired strong volume growth — Q4 international cannabis +68%, Canada medical +27% YoY, FY net revenue +6% to C$284.6M — with a -$0.06 EPS miss on $71.2M Q4 revenue. The sector grows revenue and still bleeds.
• Roughly 31% cannabis revenue mix means TLRY now correlates meaningfully to craft-beverage volumes and European medical distribution, which mutes the reform-beta the group is bought for. On a genuine rescheduling headline, purer US-exposed names should outrun it.
• German medical cannabis volumes are the one exposure uncorrelated to US federal policy, and the Panama launch (2026-07-09) extends that decoupling.
• The ~2026-11-12 hemp recriminalization date is a shared sector catalyst affecting all licensed operators; H.R. 7024 deferring it to 2028 would be a group-wide negative.